SOUTH SAN FRANCISCO, Calif., Sept. 30, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that Peter Langecker, M.D., Ph.D., President and Chief Executive Officer, will provide a corporate overview at the 12th Annual BIO Investor Forum conference on October 8, 2013 at 4:00 PT at the Palace Hotel, San Francisco, California.
To access the live audio webcast of the presentation, please log on through a link located in the Investors section of OXiGENE's website at www.oxigene.com, under the Events and Presentations tab. A replay of the webcast will be available one hour after the conclusion of the live event.
OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer. The Company's major focus is developing vascular disrupting agents (VDAs) that selectively disrupt abnormal blood vessels associated with solid tumor progression. OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.
CONTACT: Investor and Media Contact: firstname.lastname@example.org 650-635-7000